Amedeo Smart

Free Medical Literature Service

 

Amedeo

Alzheimer's Disease
  Free Subscription

Articles published in
Nat Med
    April 2025

  1. Cerebrospinal fluid biomarker predicts dementia onset and progression in Alzheimer's disease.
    Nat Med. 2025 Apr 28. doi: 10.1038/s41591-025-03700.
    >> Share


  2. Microglia drive amyloid-beta clearance in immunized patients with Alzheimer's disease.
    Nat Med. 2025 Apr 22. doi: 10.1038/s41591-025-03677.
    >> Share

  3. O'LEARY K
    Anti-amyloid could help prevent genetic form of Alzheimer's disease.
    Nat Med. 2025 Apr 17. doi: 10.1038/d41591-025-00026.
    >> Share

  4. PALMQVIST S, Warmenhoven N, Anastasi F, Pilotto A, et al
    Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform.
    Nat Med. 2025 Apr 9. doi: 10.1038/s41591-025-03622.
    >> Share

  5. ANDRIEU S, Bateman RJ, Bereczki E, Bose N, et al
    Harnessing artificial intelligence to transform Alzheimer's disease research.
    Nat Med. 2025 Apr 1. doi: 10.1038/s41591-025-03632.
    >> Share

    March 2025
  6. HORIE K, Salvado G, Koppisetti RK, Janelidze S, et al
    Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease.
    Nat Med. 2025 Mar 31. doi: 10.1038/s41591-025-03617.
    >> Share

  7. OH HS, Urey DY, Karlsson L, Zhu Z, et al
    A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease.
    Nat Med. 2025 Mar 31. doi: 10.1038/s41591-025-03565.
    >> Share

  8. VAN OLST L, Simonton B, Edwards AJ, Forsyth AV, et al
    Author Correction: Microglial mechanisms drive amyloid-beta clearance in immunized patients with Alzheimer's disease.
    Nat Med. 2025 Mar 28. doi: 10.1038/s41591-025-03664.
    >> Share

  9. GRANDE G, Valletta M, Rizzuto D, Xia X, et al
    Blood-based biomarkers of Alzheimer's disease and incident dementia in the community.
    Nat Med. 2025 Mar 26. doi: 10.1038/s41591-025-03605.
    >> Share

  10. RAJJI TK, Baksh SN, Shade DM, Ismail Z, et al
    Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.
    Nat Med. 2025 Mar 25. doi: 10.1038/s41591-025-03569.
    >> Share

  11. RASH BG, Ramdas KN, Agafonova N, Naioti E, et al
    Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.
    Nat Med. 2025 Mar 10. doi: 10.1038/s41591-025-03559.
    >> Share

  12. VAN OLST L, Simonton B, Edwards AJ, Forsyth AV, et al
    Microglial mechanisms drive amyloid-beta clearance in immunized patients with Alzheimer's disease.
    Nat Med. 2025 Mar 6. doi: 10.1038/s41591-025-03574.
    >> Share

  13. MOUTINHO S
    Women twice as likely to develop Alzheimer's disease as men - but scientists do not know why.
    Nat Med. 2025;31:704-707.
    >> Share

  14. DUFF EP, Zetterberg H, Heslegrave A, Dehghan A, et al
    Plasma proteomic evidence for increased beta-amyloid pathology after SARS-CoV-2 infection.
    Nat Med. 2025;31:797-806.
    >> Share

    February 2025
  15. ISLAM T, Hill E, Abrahamson EE, Servaes S, et al
    Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's disease.
    Nat Med. 2025 Feb 10. doi: 10.1038/s41591-024-03400.
    >> Share

  16. LLIBRE-GUERRA JJ, Fernandez MV, Joseph-Mathurin N, Bian S, et al
    Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia.
    Nat Med. 2025 Feb 10. doi: 10.1038/s41591-025-03494.
    >> Share

    December 2024
  17. MOGUILNER S, Baez S, Hernandez H, Migeot J, et al
    Brain clocks capture diversity and disparities in aging and dementia across geographically diverse populations.
    Nat Med. 2024;30:3646-3657.
    >> Share

    July 2024
  18. FORTEA J, Vaque-Alcazar L, Pegueroles J, Alcolea D, et al
    Reply to: Challenges to identifying risk versus protective factors in Alzheimer's disease.
    Nat Med. 2024 Jul 18. doi: 10.1038/s41591-024-03159.
    >> Share

  19. PAPPALETTERA C, Carrarini C, Cappa S, Caraglia N, et al
    Challenges to identifying risk versus protective factors in Alzheimer's disease.
    Nat Med. 2024 Jul 18. doi: 10.1038/s41591-024-03158.
    >> Share

  20. ROSENZWEIG N, Kleemann KL, Rust T, Carpenter M, et al
    Sex-dependent APOE4 neutrophil-microglia interactions drive cognitive impairment in Alzheimer's disease.
    Nat Med. 2024 Jul 3. doi: 10.1038/s41591-024-03122.
    >> Share

    June 2024
  21. JACK CR JR, Andrews SJ, Beach TG, Buracchio T, et al
    Revised criteria for the diagnosis and staging of Alzheimer's disease.
    Nat Med. 2024 Jun 28. doi: 10.1038/s41591-024-02988.
    >> Share

  22. FORTEA J, Pegueroles J, Alcolea D, Belbin O, et al
    Publisher Correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease.
    Nat Med. 2024 Jun 17. doi: 10.1038/s41591-024-03127.
    >> Share

    May 2024
  23. SHANKS HRC, Chen K, Reiman EM, Blennow K, et al
    p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.
    Nat Med. 2024 May 17. doi: 10.1038/s41591-024-02977.
    >> Share

  24. FORTEA J, Pegueroles J, Alcolea D, Belbin O, et al
    APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease.
    Nat Med. 2024 May 6. doi: 10.1038/s41591-024-02931.
    >> Share

  25. XU Q, Liang Z, Huang Y
    APOE4 homozygosity is a new genetic form of Alzheimer's disease.
    Nat Med. 2024 May 6. doi: 10.1038/s41591-024-02923.
    >> Share

    March 2024
  26. O'LEARY K
    A timeline of biomarker changes before Alzheimer's disease.
    Nat Med. 2024 Mar 15. doi: 10.1038/d41591-024-00018.
    >> Share

    February 2024
  27. BARTHELEMY NR, Salvado G, Schindler S, He Y, et al
    Highly Accurate Blood Test for Alzheimer's Disease Comparable or Superior to Clinical CSF Tests.
    Nat Med. 2024 Feb 21. doi: 10.1038/s41591-024-02869.
    >> Share

    January 2024
  28. JUCKER M, Walker LC
    Evidence for iatrogenic transmission of Alzheimer's disease.
    Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02768.
    >> Share

  29. BANERJEE G, Farmer SF, Hyare H, Jaunmuktane Z, et al
    Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone.
    Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02729.
    >> Share

  30. O'LEARY K
    Modeling real-world data to repurpose drugs for Alzheimer's disease.
    Nat Med. 2024 Jan 18. doi: 10.1038/d41591-024-00003.
    >> Share

    December 2023
  31. O'LEARY K
    Positive results in Alzheimer's disease trials.
    Nat Med. 2023;29:2973.
    >> Share

    November 2023
  32. SANCHEZ VELA P, Trowbridge JJ, Levine RL
    Author Correction: Clonal hematopoiesis, aging and Alzheimer's disease.
    Nat Med. 2023 Nov 20. doi: 10.1038/s41591-023-02718.
    >> Share

    October 2023
  33. MUMMERY CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al
    Author Correction: Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
    Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02639.
    >> Share

    September 2023
  34. LONGO FM, Massa SM
    Senolytic therapy for Alzheimer's disease.
    Nat Med. 2023 Sep 27. doi: 10.1038/s41591-023-02541.
    >> Share

  35. GONZALES MM, Garbarino VR, Kautz TF, Palavicini JP, et al
    Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.
    Nat Med. 2023 Sep 7. doi: 10.1038/s41591-023-02543.
    >> Share

  36. SELF WK, Holtzman DM
    Emerging diagnostics and therapeutics for Alzheimer disease.
    Nat Med. 2023 Sep 4. doi: 10.1038/s41591-023-02505.
    >> Share

    August 2023

  37. Events in the brain during the evolution of Alzheimer's disease.
    Nat Med. 2023 Aug 7. doi: 10.1038/s41591-023-02477.
    >> Share

  38. JOHNSON ECB, Bian S, Haque RU, Carter EK, et al
    Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.
    Nat Med. 2023 Aug 7. doi: 10.1038/s41591-023-02476.
    >> Share


  39. A fluid biomarker accurately detects tau aggregate pathology in Alzheimer's disease.
    Nat Med. 2023 Aug 2. doi: 10.1038/s41591-023-02468.
    >> Share

  40. PALMQVIST S, Rossi M, Hall S, Quadalti C, et al
    Cognitive effects of Lewy body pathology in clinically unimpaired individuals.
    Nat Med. 2023;29:1971-1978.
    >> Share

  41. QUADALTI C, Palmqvist S, Hall S, Rossi M, et al
    Clinical effects of Lewy body pathology in cognitively impaired individuals.
    Nat Med. 2023;29:1964-1970.
    >> Share

    July 2023
  42. O'LEARY K
    Putting the brakes on Alzheimer's disease.
    Nat Med. 2023 Jul 31. doi: 10.1038/d41591-023-00067.
    >> Share

  43. HORIE K, Salvado G, Barthelemy NR, Janelidze S, et al
    CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.
    Nat Med. 2023 Jul 13. doi: 10.1038/s41591-023-02443.
    >> Share

  44. SANCHEZ VELA P, Trowbridge JJ, Levine RL
    Clonal hematopoiesis, aging and Alzheimer's disease.
    Nat Med. 2023 Jul 4. doi: 10.1038/s41591-023-02406.
    >> Share

    June 2023
  45. BOUZID H, Belk JA, Jan M, Qi Y, et al
    Clonal hematopoiesis is associated with protection from Alzheimer's disease.
    Nat Med. 2023 Jun 15. doi: 10.1038/s41591-023-02397.
    >> Share

    May 2023
  46. BELLAVER B, Povala G, Ferreira PCL, Ferrari-Souza JP, et al
    Astrocyte reactivity influences amyloid-beta effects on tau pathology in preclinical Alzheimer's disease.
    Nat Med. 2023 May 29. doi: 10.1038/s41591-023-02380.
    >> Share

  47. LJUBENKOV PA, Rabinovici GD
    Silencing tau to treat early Alzheimer's disease.
    Nat Med. 2023 May 17. doi: 10.1038/s41591-023-02357.
    >> Share

  48. LOPERA F, Marino C, Chandrahas AS, O'Hare M, et al
    Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man.
    Nat Med. 2023 May 15. doi: 10.1038/s41591-023-02318.
    >> Share

    April 2023
  49. MUMMERY CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al
    Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
    Nat Med. 2023 Apr 24. doi: 10.1038/s41591-023-02326.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016